Nurix Therapeutics logo

Nurix Therapeutics

NRIX | NASDAQ
Chart Builder DCF Calculator
$14.73
-$0.75 (-4.84%)
At close: Nov 16, 2026, 4:00 PM ET
$14.92
+$0.19 (+1.29%)
After-hours: Nov 16, 2026, 7:30 PM ET
-4.84%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
79.2
+2.0 pts
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #24/1021 (Top 2%)

Key Statistics

Market Data

Market Cap $1.61B
1D Range
14.68 15.60
52W Range
12.68 27.79

Valuation (TTM)

PE 6.38
PB 1.66
EV/EBITDA 1.94

Valuation (NTM)

Forward PE 5.69
Forward PEG -0.03
Price Target $34.00
Loading financial charts...

Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer,...

Sector Healthcare
Industry Biotechnology
Employees 317
IPO Date Jul 24, 2020
Fiscal Year December - November

Latest News

Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer

5 days ago · globenewswire.com

Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
Nurix Therapeutics to Participate in Upcoming Investor Conferences

6 days ago · globenewswire.com

Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

1 month ago · seekingalpha.com

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

1 month ago · zacks.com

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

1 month ago · globenewswire.com

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

1 month ago · globenewswire.com

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

1 month ago · globenewswire.com

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

2 months ago · seekingalpha.com

Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Here's Why You Should Add NRIX Stock to Your Portfolio Now

2 months ago · zacks.com

Here's Why You Should Add NRIX Stock to Your Portfolio Now

Earnings

Next Earnings
Jan 27, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
14
Consensus
Buy
Price Target
$34.00
Upside
+130.82%
Buy (13)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.